HCM
CRSP icon

Highlander Capital Management’s CRISPR Therapeutics CRSP Stock Holding History

Highlander Capital Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-100
Closed -$6.26K – 962
2023
Q4 		$6.26K Hold
100
– – ﹤0.01% 782
2023
Q3 		$5K Buy
+100
New +$5.17K ﹤0.01% 758

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Highlander Capital Management's CRSP Position: Q1 2024 in Review

Highlander Capital Management sold out of CRISPR Therapeutics (CRSP) in Q1 2024, closing a stake of 100 shares — an estimated $6.26K sold.

Highlander Capital Management first reported a position in CRSP in Q3 2023 and held it in 2 quarters. The position peaked at $6.26K in Q4 2023. 484 funds tracked by Wall St. Rank hold CRSP as of Q1 2024.

  • Highlander Capital Management reported no remaining CRISPR Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Highlander Capital Management sold 100 CRISPR Therapeutics shares in Q1 2024, an estimated $6.26K.
  • Highlander Capital Management first reported a position in CRISPR Therapeutics in Q3 2023 and held it in 2 quarters.
  • Highlander Capital Management's CRISPR Therapeutics position peaked at $6.26K in Q4 2023.
  • 484 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2024.

Based on Highlander Capital Management's 13F filing for Q1 2024, filed 20 May 2024.